Organogenesis Holdings Inc. Earnings Recaps
Q2 2026
Aug 10, 2026
Shares of Organogenesis Holdings plunged 21.5% following the Q2 2026 earnings release, driven primarily by a significant revenue decline and slower-than-expected recovery in the skin substitute market amid ongoing reimbursement headwinds from recent CMS policy changes.
Key takeaways
- Total revenue fell 58% year-over-year, largely due to a 61% plunge in Advanced Wound Care product sales.
- Although there was an 18% sequential increase in net product revenue quarter-over-quarter, this improvement was insufficient to offset continued year-over-year pressure.
- The 30% increase in wound care unit volumes quarter-over-quarter reflects market share gains but within an overall contracting market.
- CMS policy reforms since late 2025 continue to suppress market demand and delay recovery; management acknowledged revenue fell short of previous expectations.
- The company is pursuing strategic cost reductions and investing in clinical evidence development while exploring new markets with its ReNu program, though these initiatives have yet to offset near-term headwinds.
Q3 2025
Nov 8, 2025
Organogenesis Holdings reported strong third quarter results for 2025, driven by a 31% increase in Advanced Wound Care product sales and strategic advancements in Medicare payment reforms, positioning the company favorably for future growth.
Key takeaways
- Q3 revenues exceeded guidance, with Advanced Wound Care sales up 31% year-over-year and Surgical & Sports Medicine sales climbing 25%.
- The finalization of Medicare physician fee schedules marks a significant development, offering expanded access and potential for higher reimbursement for PMA products.
- Progress on the ReNu program includes favorable clinical results, FDA RMAT designation, and an upcoming meeting scheduled for December to discuss the BLA submission.
- The company maintained its competitive edge through strong brand equity and established customer relationships in the evolving skin substitute market.
- Organogenesis is well-positioned to leverage changes in Medicare policy and drive innovation in regenerative medicine.